You have read all your free articles, to continue reading subscribe to read the rest of this content.
Shares of Ipsen and partner Active Biotech plunged last week after Ipsen’s experimental prostate cancer drug Tasquinimod failed during a Phase III trial. Active’s shares dropped 60 percent and Ipsen’s went down by 10 percent. “The data at hand is unambiguous and cannot motivate further Already a subscriber Login You…
Medivir AB has enrolment of the first patient into a randomized double-blind phase IIa clinical study of the in-house developed cathepsin K inhibitor MIV-711 in patients with moderate knee osteoarthritis (OA). The phase IIa study will enrol 240 patients into 3 arms, each with approximately 80 paAlready a subscriber Login You…
Oncopeptides has presented updated data from its ongoing Phase 2 ANCHOR (OP-104) triple combination study. In the data presented at the ASH Annual Meeting 2019, melflufen and dexamethasone demonstrated positive efficacy in combination with daratumumab or bortezomib in patients with relapsed/refraAlready a subscriber Login You have read all your free…
The company has completed treatment of 25% of patients in the STAR trial of its medical device, SiPore15, and is well on track to finalize results by Q4 of this year. The company also reports that treatment compliance is good and the safety profile continues to look positive. STAR trial…
